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Impact of lung function on exacerbations, 
health care utilization, and costs among patients 
with COPD
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Jessica Marvel2
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liya Wang1
Judith J stephenson1
David M Mannino3
1healthCore Inc., Wilmington, 
De, 2novartis Pharmaceuticals 
Corporation, east hanover, 
nJ, 3University of Kentucky, 
lexington, KY, Usa
Objective: To evaluate the impact of lung function, measured as forced expiratory volume in 
1 second (FEV
1
) % predicted, on health care resource utilization and costs among patients with 
COPD in a real-world US managed-care population.
Methods: This observational retrospective cohort study utilized administrative claim data aug-
mented with medical record data. The study population consisted of patients with one or more 
medical claims for pre- and postbronchodilator spirometry during the intake period (July 1, 2012 
to June 30, 2013). The index date was the date of the earliest medical claim for pre- and postbron-
chodilator spirometry. Spirometry results were abstracted from patients’ medical records. Patients 
were divided into two groups (low FEV
1
% predicted [,50%] and high FEV
1
% predicted [$50%]) 
based on the 2014 Global Initiative for Chronic Obstructive Lung Disease report. Health care 
resource utilization and costs were based on the prevalence and number of discrete encounters 
during the 12-month postindex follow-up period. Costs were adjusted to 2014 US dollars.
Results: A total of 754 patients were included (n=297 low FEV
1
% predicted group, n=457 high 
FEV
1
% predicted group). COPD exacerbations were more prevalent in the low FEV
1
% predicted 
group compared with the high group during the 12-month pre- (52.5% vs 39.6%) and postindex 
periods (49.8% vs 36.8%). Mean (standard deviation) follow-up all-cause and COPD-related costs 
were $27,380 ($38,199) and $15,873 ($29,609) for patients in the low FEV
1
% predicted group, 
and $22,075 ($28,108) and $10,174 ($18,521) for patients in the high group. In the multivariable 
analyses, patients in the low FEV
1
% predicted group were more likely to have COPD exacerbations 
and tended to have higher COPD-related costs when compared with patients in the high group.
Conclusion: Real-world data demonstrate that patients with COPD who have low FEV
1
% 
predicted levels use more COPD medications, have more COPD exacerbations, and incur higher 
COPD-related health care costs than those with high FEV
1
% predicted levels.
Keywords: COPD, lung function, FEV
1
, exacerbations, health care resource utilization and 
costs
Introduction
COPD is characterized by a restricted airway and functional impairment.1 The 
symptoms of COPD, including dyspnea, cough, and sputum production, negatively 
affect a patient’s health status and may lead to disability. Airflow restriction is 
progressive and often not spontaneously reversible; therefore, the goal of COPD 
therapy is to reduce symptoms, prevent exacerbations, and improve lung function. 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classifies COPD 
based on history of exacerbations and symptoms, as well as objective measures of 
airflow limitation.2 Spirometry – specifically, forced expiratory volume in 1 second 
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(FEV
1
) – is a widely accepted objective and validated 
measure of pulmonary function.3–5 The US Food and Drug 
Administration requires spirometry improvements as a pri-
mary outcome in clinical trials of bronchodilator medications 
for COPD. In clinical practice, however, patient symptoms 
and health status are commonly used for clinical assessment 
of COPD.6
Numerous studies have demonstrated a correlation 
between poor lung function and increased COPD symptoms 
and exacerbations,7–17 and improvements in lung function are 
associated with health status gains in people with COPD.6 
Studies examining the relationship between FEV
1
 and 
patient-reported outcomes concluded that changes in FEV
1
 
predict changes in health status.6,11 Therefore, therapies 
that improve FEV
1
 will likely improve clinical and patient-
reported outcomes as well.11
COPD exacerbations are often sufficiently serious to 
require emergency treatment or hospitalization,16 and are 
thus associated with substantial increases in health care 
costs.17 A retrospective study measuring the cost of COPD 
exacerbations, identified from administrative claim data 
and assessed by quarter and severity of the exacerbation, 
found the mean total cost of a severe exacerbation (ie, an 
exacerbation [with a claim for oral or parenteral cortico-
steroids on the same day or within 7 days following a 
COPD claim] involving either a hospitalization on the 
same day or death within 7 days of the COPD claim) was 
US $17,016 per patient-quarter, compared with $6,628 per 
patient-quarter for a nonsevere exacerbation (ie, an exac-
erbation involving neither a hospitalization on the same 
day nor death within 7 days of the COPD claim).17 While 
previous research has largely examined the relationship 
between claim-determined exacerbations and costs, studies 
that have explored the relationship between clinically 
determined lung function (ie, measured by spirometry) and 
health care resource utilization (HCRU) and costs18–30 are 
limited to studies based on data gathered more than a decade 
ago,21,22,26,29 populations of fewer than 500 patients,22,25,27,28 
or patients recruited from single centers.26,27,30 Addition-
ally, a number of those studies were performed outside 
the US.18–21,23–25,28,29 Since COPD treatment and health care 
utilization patterns, as well as costs, vary considerably 
between countries,28 the results from these studies, while of 
interest, cannot be generalized to a US population. To fill 
this knowledge gap, this study evaluated the impact of 
FEV
1
 levels on HCRU, including COPD exacerbations, and 
direct costs among patients with COPD in a real-world US 
managed-care population.
Methods
Study design and patient identification
This study was an observational retrospective cohort study 
utilizing administrative claim data augmented with medical 
record data. The patient sample was identified from medical 
and pharmacy claims in the HealthCore Integrated Research 
Database, a large administrative claims database with 
claims from 14 geographically dispersed US health plans, 
with service dates during the study period between July 
1, 2011 and June 30, 2014. The patient inclusion criteria 
based on administrative claims data were: one or more 
medical claims for pre- and postbronchodilator spirometry 
(Current Procedural Terminology code 94060) during the 
study intake period, which extended from July 1, 2012 
through June 30, 2013 (index date = date of the earliest 
medical claim for pre- and postbronchodilator spirometry 
in the intake period); one or more medical claims for an 
inpatient stay or emergency department (ED) visit associ-
ated with COPD (International Classification of Diseases, 
ninth revision, clinical modification [ICD-9-CM] diagnosis 
codes 491.xx, 492.xx, and 496.xx); or two or more medical 
claims with distinct service dates for COPD in an office or 
other outpatient setting during the study period. In addition, 
all patients were 40 years of age or older on the index date, 
had at least 12 months preindex (baseline) and 12 months 
postindex (follow-up) continuous medical and pharmacy 
enrollment, were insured with only commercial or Medicare 
Advantage health insurance during the study period, and 
were patients whose medical records could be requested for 
medical record studies (Figure 1).
Medical record review
Medical record data were required to supplement information 
not available in the administrative claims data (eg, FEV
1
% 
predicted value). Providers who were associated with the 
index spirometry test who had seen the patient at least once 
in the 12-month period prior to the index date and had valid 
contact information, were identified. A patient/provider 
list was generated and sent to HealthCore’s medical record 
vendor, who requested the medical records of the patients 
on the list from their identified providers. A standardized 
data collection form was developed and used to abstract the 
relevant clinical data. Patients with a diagnosis of COPD, 
a postbronchodilator FEV
1
/forced vital capacity (FVC) 
ratio ,0.7, and at least one post-bronchodilator FEV
1
% 
predicted value documented in the medical record review 
period, defined as between index date - 365 days and index 
date + 30 days, were included in the analyses.
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The number of targeted completed medical record 
abstractions was set at 800, based on margin-of-error 
estimations ranging from ±4.9% to ±6.57% at a 95% confi-
dence level. The study was approved by the New England 
Institutional Review Board. A Waiver of Authorization 
was obtained from the New England Institutional Review 
Board to acquire and review medical records without patient 
signature.
After the medical record abstractions were completed, 
patients’ medical record data were merged with their admin-
istrative claims data using unique patient identifiers for 
analysis purposes. The patient cohort was stratified into two 
groups, based on the postbronchodilator FEV
1
% predicted 
value according to the classification of severity of airflow 
limitation in COPD specified in the 2014 GOLD report.2 
Patients meeting the GOLD criteria for mild (GOLD I) or 
moderate (GOLD II) COPD severity (ie, postbronchodilator 
FEV
1
 50% predicted or higher) were categorized as high 
FEV
1
% predicted, and patients meeting the GOLD criteria 
for severe (GOLD III) or very severe (GOLD IV) COPD 
(ie, FEV
1
 less than 50% predicted) were categorized as low 
FEV
1
% predicted.
study measures
Baseline variables assessed from the administrative claims 
included demographic characteristics (eg, age, sex, provider 
specialty associated with index spirometry test) and clinical 
characteristics during the 12-month preindex period, such as 
comorbidities (measured using the Quan–Charlson Comor-
bidity Index)31 and conditions, use of oxygen therapy, and 
dyspnea. Criteria for COPD exacerbations were based on the 
2014 GOLD report,2 and were defined as inpatient COPD 
exacerbations (an inpatient stay with COPD [ICD-9-CM 
codes 491.xx, 492.xx, 496.xx] as the primary diagnosis), 
ED COPD exacerbations (an ED visit with COPD as the 
primary diagnosis [ED visits followed by hospitaliza-
tions were not included, as they were considered inpatient 
hospitalizations]), and ambulatory COPD exacerbations 
(a physician office or other outpatient visit with COPD 
diagnosis in any position of a medical claim and receipt of 
corticosteroids and antibiotics within 7 days following the 
physician office/other outpatient visit) during the 12-month 
pre- and 12-month postindex periods. The hierarchy applied 
to create the type of COPD exacerbation for an exacerbation 
episode was inpatient COPD exacerbation . ED COPD 
exacerbation . ambulatory COPD exacerbation. COPD 
medication treatment patterns were evaluated at 12 months 
pre- and 12 months postindex, and included any inhaled cor-
ticosteroids (ICS), long-acting muscarinic agents (LAMAs), 
long-acting β-agonists (LABAs), short-acting muscarinic 
antagonists, or short-acting inhaled β
2
-adrenergic agonists 
used as a single or combination therapy in addition to other 
COPD medications, including phosphodiesterase-4 inhibi-
tors and xanthenes.
HCRU and costs were based on the prevalence and 
number of discrete encounters during the 12-month pre- and 
12-month postindex periods. Utilization was broken down 
by site of care (eg, physician office visits, other outpatient 
visits, ED visits, and inpatient hospitalizations) and pharmacy 
dispensing. Costs were determined based on site of care, 
and were reported in aggregate as total costs paid across all 
resources (medical plus pharmacy) in US dollars. Costs are 
Figure 1 study design.
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presented as the combined amount paid by both the health 
plan and the patient to providers. Patient out-of-pocket costs 
included all coinsurance, deductibles, copayments, or other 
patient outlays related to specific medical claims. All costs 
were adjusted to 2014 dollars, given the most recent medi-
cal care price index information provided by the Bureau of 
Labor Statistics at the time the analyses were performed.32 
COPD-related utilization and costs were captured from medi-
cal claims containing ICD-9-CM diagnosis codes for COPD 
(ICD-9-CM codes 491.xx, 492.xx, and 496.xx) and pharmacy 
claims containing generic product identifier codes for COPD-
related medications. Additional clinical data abstracted from 
the medical records included confirmation of the COPD 
diagnosis, spirometry test results, asthma diagnosis, dyspnea, 
smoking status, and race.
statistical analyses
Descriptive statistics included means (standard deviation 
[SD], median) and frequencies and percentages for con-
tinuous and categorical data, respectively. An unadjusted 
analysis was conducted with comparisons between high 
and low FEV
1
% predicted cohorts. Logistic regression 
models were developed to examine the association between 
postbronchodilator FEV
1
% predicted and occurrence of 
COPD exacerbations in the 12-month postindex period. The 
dependent variable was occurrence of at least one COPD 
exacerbation in the 12-month follow-up period. Due to the 
non-normal distribution and skewed nature of the cost data, 
generalized linear models with gamma distribution and 
log link function were applied to examine the association 
between postbronchodilator FEV
1
% predicted and all-cause 
health care direct costs in the 12-month postindex period, and 
the association between postbronchodilator FEV
1
% predicted 
and COPD-related health care direct costs in the 12-month 
postindex period. Analyses were performed using SAS 9.4 
(SAS Institute Inc, Cary, NC, USA), with a two-sided 5% 
significance level for all statistical tests.
Results
study population
Of the 4,349 patients who were identified from the admin-
istrative claims database (Figure S1) and whose medical 
records were requested, 2,507 medical records were obtained 
and 2,480 medical records reviewed for eligibility criteria. 
Of these, the medical records of 754 patients contained all 
required clinical data, and were included in the final analysis 
(Figure S2); 1,726 medical records were excluded, because 
there were no documented spirometry results (644 records), 
no documented postbronchodilator FEV
1
% (246 records), no 
documented postbronchodilator FEV
1
/FVC ratio ,0.7 (731 
records), no documented diagnosis of COPD (85 records), 
or incorrect patient information (20 records).
Baseline patient characteristics from 
claims data
The mean age of patients included in the analyses was 69.4 
(SD 8.81) years in the low FEV
1
% predicted group and 
71.3 (SD 9.97) years in the high FEV
1
% predicted group 
(Table 1). Slightly more than half were women (54.4%). 
Pulmonologists were the predominant provider specialty 
associated with the index spirometry tests in both the low 
FEV
1
% predicted group (79.8%) and high FEV
1
% predicted 
group (73.3%).
The most prevalent comorbidities in both cohorts were 
hypertension (57.6% low group vs 63.5% high group), 
ischemic heart disease (27.3% low group vs 28.4% high 
group), and diabetes (23.6% low group vs 22.5% high group). 
Compared with patients in the high FEV
1
% predicted group, 
a greater percentage of patients in the low FEV
1
% predicted 
group had oxygen therapy (42.1% low group vs 19.0% high 
group) during the baseline period.
Baseline clinical characteristics from 
medical records
All 754 patients had a diagnosis of COPD confirmed in their 
medical records. The mean (SD) postbronchodilator FEV
1
% 
predicted values were 37.2% (8.38%) and 69.1% (14.51%) in 
the low and high FEV
1
% predicted groups, respectively. The 
mean (SD) postbronchodilator FEV
1
/FVC ratio was 45.5% 
(10.71%) in the low FEV
1
% predicted group and 58.8% 
(7.58%) in the high FEV
1
% predicted group. A majority of 
patients were Caucasian/white (82.8% low group vs 79.4% 
high group), had experienced dyspnea (77.4% low group vs 
70.5% high group), and had a history of smoking (74.1% 
low group vs 76.8% high group). An asthma diagnosis was 
documented in 17.2% of patients in the low FEV
1
% predicted 
group vs 19.9% in the high group (Table 2).
Utilization of COPD medications from 
claims data
Among patients in the low and high FEV
1
% predicted groups, 
utilization of COPD medications during the baseline and 
follow-up periods were: any ICS (67.3% vs 46% and 70.7% 
vs 54.9%), any LABA (66.3% vs 41.8% and 68.4% vs 
51%), any LAMA (51.2% vs 35.7% and 54.5% vs 41.6%), 
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Table 1 Baseline demographic and clinical characteristics from claims
Total  
(n=754)
Low FEV1%  
predicteda (n=297)
High FEV1%  
predicteda (n=457)
Female, n (%) 410 (54.4) 154 (51.9) 256 (56.0)
age at index (years), mean (sD, median) 70.6 (9.57, 72) 69.4 (8.81, 70) 71.3 (9.97, 72)
age group, n (%)
40–64 years 199 (26.4) 82 (27.6) 117 (25.6)
65–74 years 279 (37.0) 126 (42.4) 153 (33.5)
$75 years 276 (36.6) 89 (30.0) 187 (40.9)
Provider specialty associated with index  
spirometry test, n (%)
Pulmonologist 572 (75.9) 237 (79.8) 335 (73.3)
Primary care physicianb 161 (21.4) 52 (17.5) 109 (23.9)
Other 21 (2.8) 8 (2.7) 13 (2.8)
Most prevalent comorbidities, n (%)
hypertension 461 (61.1) 171 (57.6) 290 (63.5)
Ischemic heart disease 211 (28.0) 81 (27.3) 130 (28.4)
Diabetes 173 (22.9) 70 (23.6) 103 (22.5)
asthma 165 (21.9) 63 (21.2) 102 (22.3)
Peripheral vascular disease 140 (18.6) 55 (18.5) 85 (18.6)
COPD-related infection 138 (18.3) 58 (19.5) 80 (17.5)
Congestive heart failure 124 (16.4) 50 (16.8) 74 (16.2)
Cancer 109 (14.5) 34 (11.4) 75 (16.4)
heart failure 105 (13.9) 43 (14.5) 62 (13.6)
Atrial fibrillation 98 (13.0) 28 (9.4) 70 (15.3)
Cerebrovascular disease 80 (10.6) 31 (10.4) 49 (10.7)
Oxygen therapy, n (%) 212 (28.1) 125 (42.1) 87 (19.0)
Dyspnea, n (%) 369 (48.9) 159 (53.5) 210 (46.0)
QCI, mean (sD, median) 2.5 (1.99, 2) 2.4 (1.97, 2) 2.5 (2.01, 2)
Notes: alow FeV1% predicted defined as FEV1 ,50% predicted, high FeV1% predicted defined as FEV1 $50% predicted; 
bincluded family/general and internal medicine.
Abbreviations: FeV1, forced expiratory volume in 1 second; QCI, Quan–Charlson Comorbidity Index; sD, standard deviation.
Table 2 Baseline clinical characteristics from medical records
Total  
(n=754)
Low FEV1%  
predicteda (n=297)
High FEV1%  
predicteda (n=457)
Spirometry test results
Postbronchodilator FeV1% predicted, mean (sD, median) 56.6 (19.96, 56) 37.2 (8.38, 39) 69.1 (14.51, 66)
Postbronchodilator FeV1/FVC ratio (%), mean (sD, median) 53.6 (11.07, 55) 45.5 (10.71, 44) 58.8 (7.58, 60)
Documented asthma diagnosis, n (%)
Yes 142 (18.8) 51 (17.2) 91 (19.9)
no 232 (30.8) 84 (28.3) 148 (32.4)
Unknown/not documented 380 (50.4) 162 (54.5) 218 (47.7)
Documented dyspnea, n (%)
Yes 552 (73.2) 230 (77.4) 322 (70.5)
no 82 (10.9) 21 (7.1) 61 (13.3)
Unknown/not documented 120 (15.9) 46 (15.5) 74 (6.2)
Documented smoking status, n (%)
Current smoker 163 (21.6) 58 (19.5) 105 (23.0)
Former smoker 408 (54.1) 162 (54.5) 246 (53.8)
never-smoker 35 (4.6) 12 (4.0) 23 (5.0)
Unknown/not documented 148 (19.6) 65 (21.9) 83 (18.2)
Race, n (%)
Caucasian/white 609 (80.8) 246 (82.8) 363 (79.4)
african-american/black 18 (2.4) 5 (1.7) 13 (2.8)
Other 5 (0.7) 1 (0.3) 4 (0.9)
Unknown/not documented 122 (16.2) 45 (15.2) 77 (16.8)
Note: alow FeV1% predicted defined as FEV1 ,50% predicted, high FeV1% predicted defined as FEV1 $50% predicted.
Abbreviations: FeV1, forced expiratory volume in 1 second; sD, standard deviation; FVC, forced vital capacity.
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any short-acting muscarinic antagonist/short-acting inhaled 
β
2
-adrenergic agonist (73.4% vs 56.2% and 74.4% vs 54.5%), 
and other COPD medications (including phosphodiesterase-4 
inhibitors and xanthenes [8.1% vs 3.9% and 10.1% vs 4.4%]), 
respectively (data not shown in tables or figures).
COPD exacerbations from claims data
Within the low and high groups, 52.5% vs 39.6% of patients 
had any type of COPD exacerbation, including inpatient 
(34.7% vs 26%), ED (13.1% vs 9.8%), and ambulatory 
(23.9% vs 12.5%) exacerbations, during the 12-month 
preindex (baseline) period, while 49.8% vs 36.8% had any 
type of COPD exacerbation, including inpatient (20.9% 
vs 16.8%), ED (10.4% vs 9.4%), and ambulatory (28.3% 
vs 16.8%) exacerbations, during the 12-month postindex 
period (Figure 2).
health care resource utilization and 
costs from claims data
During the 12-month preindex period, the mean total all-
cause health care costs for the low FEV
1
% predicted group 
were $22,174 (SD $28,953) compared with $19,264 (SD 
$24,870) for the high FEV
1
% predicted group (Table 3). 
The mean COPD-related health care costs in the preindex 
period were $10,623 (SD $14,027) for the low FEV
1
% pre-
dicted group compared with $7,425 (SD $13,064) for the 
high FEV
1
% predicted group. As expected, mean costs for 
each site of care (eg, hospitalization, ED visits, physician 
office visit, etc) were higher for patients who had at least 
one instance of a corresponding service when compared to 
the overall patient population, but the directions and pat-
terns of the mean cost differences by low and high FEV
1
% 
predicted were similar for the study population as a whole 
(data not shown).
Overall, patients in the low FEV
1
% predicted group had 
similar all-cause HCRU as those in the high FEV
1
% predicted 
group during the baseline period. For COPD-related utiliza-
tion, patients in the low FEV
1
% predicted group had a higher 
mean number of physician office visits (4.3 low group vs 
3.1 high group), other outpatient services (7.9 low group 
vs 3.3 high group), and pharmacy claims (11.2 low group 
vs 6.1 high group) compared with those in the high FEV
1
% 
group (Table 3). Similarly to what was observed for costs, 
mean utilization for each site of care (eg, hospitalization, 
ED visit, physician office visit, etc) was higher for patients 
who had one or more instance of corresponding service 
when compared to that for the study population as a whole 
(data not shown).
During the 12-month postindex period, mean total all-
cause costs were 24% higher for patients in the low FEV
1
% 
predicted group than those in the high FEV
1
% predicted group 
($27,380 [SD $38,199] low group vs $22,075 [SD $28,108] 
high group; Table 4). A greater between-group difference 
was observed for mean COPD-related costs, which were 
56% higher in the low FEV
1
% predicted group compared 
with the high FEV
1
% predicted group ($15,873 [SD $29,609] 
low group vs $10,174 [SD $18,521] high group; Table 4). 
All-cause and COPD-related costs were primarily driven 
Figure 2 COPD exacerbations during the 12-month pre- and postindex periods.
Notes: low FeV1% predicted defined as FEV1 ,50% predicted; high FeV1% predicted defined as FEV1 $50% predicted. The hierarchy applied to create type of COPD 
exacerbation for an exacerbation episode was: inpatient COPD exacerbation . emergency department (eD) COPD exacerbation . ambulatory COPD exacerbation. 
a patient could have multiple types of COPD exacerbations within the baseline (12-month preindex period) and 12-month postindex periods.
Abbreviation: FeV1, forced expiratory volume in 1 second.
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Table 3 Baseline all-cause and COPD-related health care resource utilization and costs
Total  
(n=754)
Low FEV1% predicted
a 
(n=297)
High FEV1% predicted
a 
(n=457)
All-cause health care utilization and costsb,c
Inpatient hospitalizations
n (%) 271 (35.9) 113 (38.0) 158 (34.6)
hospitalizations for all patients, mean (sD, median) 0.6 (1.22, 0) 0.7 (1.16, 0) 0.6 (1.26, 0)
Cost for all patients, mean (sD, median) $7,252 ($17,611, $0) $7,374 ($19,228, $0) $7,173 ($16,498, $0)
ED visits
n (%) 181 (24.0) 65 (21.9) 116 (25.4)
eD visits for all patients, mean (sD, median) 0.4 (0.83, 0) 0.3 (0.72, 0) 0.4 (0.89, 0)
Cost for all patients, mean (sD, median) $425 ($1,326, $0) $383 ($1,301, $0) $453 ($1,342, $0)
Physician office visits
n (%) 752 (99.7) 297 (100.0) 455 (99.6)
Physician office visits for all patients, mean  
(sD, median)
12.8 (8.39, 11) 12.4 (8.09, 10) 13.1 (8.58, 12)
Cost of physician office visits for all patients, mean 
(sD, median)
$1,556 ($1,227, $1,252) $1,491 ($1,154, $1,227) $1,598 ($1,272, $1,258)
Other outpatient services
n (%) 741 (98.3) 291 (98.0) 450 (98.5)
Other outpatient services for all patients, mean 
(sD, median)
20.6 (20.37, 14) 22.3 (22.20, 17) 19.4 (19.02, 14)
Cost of other outpatient services for all patients, 
mean (sD, median)
$5,556 ($13,362, $2,564) $5,553 ($12,346, $2,661) $5,558 ($13,996, $2,487)
Pharmacy dispensing
n (%) 743 (98.5) 290 (97.6) 453 (99.1)
Claims for all patients, mean (sD, median) 44.9 (32.53, 38) 48.0 (32.83, 41) 42.9 (32.22, 37)
Cost for all patients, mean (sD, median) $5,621 ($11,356, $3,346) $7,374 ($15,647, $4,246) $4,483 ($7,124, $2,919)
Total medical costs, mean (sD, median) $14,789 ($23,644, $6,895) $14,801 ($23,928, $7,284) $14,782 ($23,484, $6,652)
Total costs (sum of medical and pharmacy cost), 
mean (sD, median)
$20,411 ($26,573, $12,243) $22,174 ($28,953, $13,262) $19,264 ($24,870, $11,149)
COPD-related health care utilization and costsb,c
Inpatient hospitalizations
n (%) 220 (29.2) 101 (34.0) 119 (26.0)
hospitalizations for all patients, mean (sD, median) 0.5 (0.92, 0) 0.5 (0.93, 0) 0.4 (0.91, 0)
Cost for all patients, mean (sD, median) $5,070 ($12,354, $0) $5,617 ($12,154, $0) $4,714 ($12,483, $0)
ED visits
n (%) 93 (12.3) 42 (14.1) 51 (11.2)
eD visits for all patients, mean (sD, median) 0.2 (0.51, 0) 0.2 (0.49, 0) 0.2 (0.53, 0)
Cost for all patients, mean (sD, median) $210 ($848, $0) $260 ($1,081, $0) $178 ($654, $0)
Physician office visits
n (%) 674 (89.4) 272 (91.6) 402 (88.0)
Physician office visits for all patients, mean  
(sD, median)
3.6 (3.24, 3) 4.3 (3.56, 4) 3.1 (2.90, 2)
Cost of physician office visits for all patients, mean 
(sD, median)
$425 ($449, $321) $510 ($501, $380) $370 ($403, $277)
Other outpatient services
n (%) 430 (57.0) 196 (66.0) 234 (51.2)
Other outpatient services for all patients, mean 
(sD, median)
5.1 (9.56, 1) 7.9 (11.66, 2) 3.3 (7.37, 1)
Cost of other outpatient services for all patients, 
mean (sD, median)
$1,027 ($3,656, $55) $1,536 ($5,255, $242) $697 ($1,967, $10)
Pharmacy dispensing
n (%) 613 (81.3) 261 (87.9) 352 (77.0)
Claims for all patients, mean (sD, median) 8.1 (9.26, 5) 11.2 (10.70, 9) 6.1 (7.53, 4)
Cost for all patients, mean (sD, median) $1,952 ($2,247, $1,211) $2,700 ($2,636, $2,039) $1,466 ($1,795, $729)
Total medical costs, mean (sD, median) $6,732 ($13,263, $1,180) $7,922 ($13,647, $2,300) $5,959 ($12,964, $701)
Total costs (sum of medical and pharmacy costs), 
mean (sD, median)
$8,684 ($13,533, $4,214) $10,623 ($14,027, $6,142) $7,425 ($13,064, $3,072)
Notes: alow FeV1 predicted was defined as FEV1 ,50% predicted; high FeV1 predicted was defined as FEV1 $50% predicted. 
bBaseline all-cause and COPD-related healthcare 
resource utilization and costs were measured in the 12-month preindex period. cCosts were adjusted to 2014 Us dollars given the most accurate and updated medical care 
price index information provided by the Bureau of labor statistics. 
Abbreviations: eD, emergency department; FeV1, forced expiratory volume in 1 second; sD, standard deviation.
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Table 4 12-month postindex all-cause and COPD-related health care resource utilization and costs
Total  
(n=754)
Low FEV1% predicted
a 
(n=297)
High FEV1% predicted
a 
(n=457)
All-cause health care utilization and costsb,c
Inpatient hospitalizations
n (%) 250 (33.4) 107 (36.0) 145 (31.7)
hospitalizations for all patients, mean (sD, median) 0.6 (1.24, 0) 0.7 (1.28, 0) 0.6 (1.22, 0)
Cost for all patients, mean (sD, median) $8.846 ($22,858, $0) $10,224 ($27,293, $0) $7,951 ($19,422, $0)
ED visits
n (%) 202 (26.8) 83 (27.9) 119 (26.0)
eD visits for all patients, mean (sD, median) 0.4 (1.28, 0) 0.4 (0.78, 0) 0.5 (1.53, 0)
Cost for all patients, mean (sD, median) $552 ($1,829, $0) $476 ($1,450, $0) $601 ($2,038, $0)
Physician office visits
Physician office visits, n (%) 753 (99.9) 297 (100.0) 456 (99.8)
Physician office visits for all patients, mean  
(sD, median)
13.5 (9.00, 12) 13.2 (8.37, 12) 13.7 (9.39, 12)
Cost of physician office visits for all patients, mean  
(sD, median)
$1,755 ($1,804, $1,370) $1,649 ($1,341, 1,328) $1,823 ($2,048, $1,406)
Other outpatient services
n (%) 747 (99.1) 296 (99.7) 451 (98.7)
Other outpatient services for all patients, mean  
(sD, median)
23.6 (22.30, 19) 27.3 (25.96, 23) 21.3 (19.22, 16)
Cost of other outpatient services for all patients, mean 
(sD, median)
$6,322 ($13,654, $3,057) $6,516 ($13,978, $3,114) $6,196 ($13,454, $2,929)
Pharmacy dispensing
Pharmacy dispensing, n (%) 747 (99.1) 295 (99.3) 452 (98.9)
Claims for all patients, mean (sD, median) 49.4 (33.77, 43) 52.2 (33.67, 46) 47.5 (33.74, 42)
Cost for all patients, mean (sD, median) $6,690 ($13,766, $3,829) $8,515 ($18,734, $4,810) $5,504 ($9,031, $3,375)
Total medical costs, mean (sD, median) $17,475 ($29,490, $6,888) $18,865 ($34,217, $7,525) $16,571 ($25,961, $6,552)
Total costs (sum of medical and pharmacy costs), mean 
(sD, median)
$24,165 ($32,539, $12,826) $27,380 ($38,199, $14,747) $22,075 ($28,108, $11,915)
COPD-related health care utilization and costsb,c
Inpatient hospitalizations
n (%) 216 (28.6) 101 (34.0) 115 (25.2)
hospitalizations for all patients, mean (sD, median) 0.5 (1.01, 0) 0.6 (1.11, 0) 0.4 (0.94, 0)
Cost for all patients, mean (sD, median) $7,625 ($21,785, $0) $9,367 ($26,658, $0) $6,493 ($17,864, $0)
ED visits
n (%) 113 (15.0) 49 (16.5) 64 (14.0)
eD visits for all patients, mean (sD, median) 0.2 (0.80, 0) 0.2 (0.53, 0) 0.2 (0.94, 0)
Cost for all patients, mean (sD, median) $257 ($1,039, $0) $247 ($9,807, $0) $263 ($1,166, $0)
Physician office visits
n (%) 713 (94.6) 292 (98.3) 421 (92.1)
Physician office visits for all patients, mean  
(sD, median)
4.5 (3.64, 42) 5.4 (3.91, 4) 3.9 (3.32, 3)
Cost of physician office visits for all patients, mean  
(sD, median)
$571 ($606, $435) $695 ($737, $530) $491 ($488, $387)
Other outpatient services
n (%) 547 (72.5) 235 (79.1) 312 (68.3)
Other outpatient services for all patients, mean  
(sD, median)
7.2 (11.13, 2) 11.2 (13.97, 5) 4.6 (7.81, 1)
Cost of other outpatient services for all patients, mean 
(sD, median)
$1,624 ($6,420, $291) $2,517 ($9,500, $916) $1,044 ($2,937, $225)
Pharmacy dispensing
n (%) 630 (83.6) 270 (90.9) 360 (78.8)
Claims for all patients, mean (sD, median) 9.2 (9.64, 7) 12.2 (11.27, 9) 7.3 (7.84, 5)
Cost for all patients, mean (sD, median) $2,341 ($2,475, $1,616) $3,047 ($2,902, $2,549) $1,883 ($2,029, $1,371)
Total COPD-related medical costs, mean (sD, median) $10,077 ($23,575, $1,769) $12,826 ($29,503, $2,620) $8,291 ($18,565, $1,034)
Total COPD-related costs (sum of medical and 
pharmacy costs), mean (sD, median)
$12,419 ($23,667, $4,901) $15,873 ($29,609, $6,868) $10,174 ($18,521, $3,918)
Notes: alow FeV1% predicted defined as FEV1 ,50% predicted, high FeV1% predicted defined as FEV1 $50% predicted; 
bevents on index date included in 12-month postindex 
period; ccosts adjusted to 2014 Us dollars, given the most accurate and updated medical care price index information provided by the Bureau of labor statistics.
Abbreviations: eD, emergency department; FeV1, forced expiratory volume in 1 second; sD, standard deviation.
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by expenditures for inpatient hospitalizations, followed by 
medications and other outpatient services.
Follow-up all-cause health care utilization of hospital-
ization, ED visits, and physician office visits were similar 
between the low and high FEV
1
% predicted groups. Patients 
in the low FEV
1
% predicted group had a higher mean number 
of other outpatient services (27.3 [SD 25.96]) compared to 
the high FEV
1
% predicted group (21.3 [SD 19.22]). They 
also had higher mean prescription costs compared with the 
high FEV
1
% predicted group ($8,515 [SD $18,734] vs $5,504 
[SD $9,031], respectively) (Table 4).
During the follow-up period, the low FEV
1
% predicted 
group had a higher percentage of COPD-related inpatient 
hospitalizations (34.0% vs 25.2%) and higher mean inpatient 
costs ($9,367 [SD $26,658]) vs ($6,493 [SD $17,864]) com-
pared to the high group. The low FEV
1
% predicted group also 
had a higher mean number of physician office visits (5.4 [SD 
3.91] vs 3.9 [SD 3.32]) and associated costs ($695 [SD $737] 
vs $491 [SD $488]), as well as a higher mean number of 
other outpatient visits (11.2 [SD 13.97] vs 4.6 [SD 7.81]) 
and mean costs ($2,517 [SD $9,500] vs $1,044 [SD $2,937]) 
compared to the high group. Pharmacy prescription utiliza-
tion was higher among patients in the low FEV
1
% predicted 
group (90.9% vs 78.8%), and associated mean costs were 
also higher for the low FEV
1
% predicted group ($3,047 
[SD $2,902] vs $1,883 [SD $2,029]) (Table 4).
Multivariable analysis
Multivariable logistic regression results indicated that any 
LABA use (single or combination therapy; odds ratio [OR] 
1.95, 95% confidence interval [CI] 1.04–3.65; P=0.0372) 
and low FEV
1
% predicted (OR 1.39, 95% CI 1.01–1.92; 
P=0.0459) were predictors of COPD exacerbations 
(Figure 3), while LAMA use (single or combination therapy) 
Figure 3 Factors associated with COPD exacerbations within the 12-month postindex period.
Notes: low FeV1% predicted defined as FEV1 ,50% predicted; high FeV1% predicted defined as FEV1 $50% predicted. logistic regression was performed with the dependent 
variable as the occurrence of COPD exacerbations within the 12-month postindex period. Odds ratios and 95% confidence intervals are reported in this figure.
Abbreviations: FeV1, forced expiratory volume in 1 second; PCP, primary care physician; ICs, inhaled corticosteroids; laBa, long-acting β-agonist; laMa, long-acting 
muscarinic agent; saMa, short-acting muscarinic antagonist; saBa, short-acting (inhaled) β2-adrenergic agonist; PDe4 inhibitors, phosphodiesterase-4 inhibitors.
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was identified as a protective factor against COPD exacerba-
tions (OR 0.72, 95% CI 0.52–1.00; P=0.0472).
Results from the cost analyses using generalized linear 
models with gamma distribution and log link showed that 
age 65–74 years (coefficient 0.31, standard error [SE] 
0.11; P=0.0066) or 75 years or older (coefficient 0.43, 
SE 0.12; P=0.0003), higher Quan–Charlson Comorbid-
ity Index score (coefficient 0.05, SE 0.02; P=0.0248), 
asthma (coefficient 0.23, SE 0.11; P=0.0480), oxygen 
therapy (coefficient 0.66, SE 0.11; P,0.0001), any ICS 
(coefficient 0.39, SE 0.18; P=0.0291), and low FEV
1
% 
predicted (coefficient 0.28, SE 0.10; P=0.0064) were 
positively associated with COPD-related costs. Pul-
monologist as provider specialty (coefficient -0.34, SE 
0.11; P=0.0018) was significantly associated with lower 
COPD-related costs compared to primary care physicians 
(Figure 4). However, low/high FEV
1
% predicted was not 
a significant predictor for all-cause health care costs (data 
not shown).
Discussion
This observational study presents real-world information 
on the demographic, clinical, and economic profiles of 
patients with COPD. Our results suggest that patients with 
low baseline FEV
1
% predicted levels tend to have greater 
utilization of COPD medications, more COPD exacerbations, 
and higher COPD-related health care costs compared with 
patients having high baseline FEV
1
% predicted levels. 
Additionally, multivariable modeling showed that having 
a low baseline FEV
1
% predicted level was a significant 
predictor of COPD exacerbations and higher COPD-related 
health care costs.
Figure 4 Factors associated with COPD-related health care costs within the 12-month postindex period.
Notes: low FeV1% predicted defined as FEV1 ,50% predicted; high FeV1% predicted defined as FEV1 $50% predicted. generalized linear models with gamma distribution 
and log link were performed with the dependent variable as COPD-related medical and pharmacy costs within the 12-month postindex period. Exponentiated coefficients 
and their corresponding 95% confidence intervals are reported in this figure.
Abbreviations: FeV1, forced expiratory volume in 1 second; PCP, primary care physician; ICs, inhaled corticosteroids; laBa, long-acting β-agonist; laMa, long-acting 
muscarinic agent; saMa, short-acting muscarinic antagonist; saBa, short-acting (inhaled) β2-adrenergic agonists; PDe4 inhibitors, phosphodiesterase-4 inhibitors.
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A significant proportion (15%–20%) of COPD patients 
also have a clinical diagnosis of asthma.33–36 Patients who met 
all study inclusion criteria and had a diagnosis of asthma were 
included in the study to reflect real-world practice.
The prevalence of any COPD exacerbations was higher in 
the low FEV
1
% predicted group than in the high FEV
1
% pre-
dicted group for both the 12-month preindex and 12-month 
postindex periods. Patients in the low FEV
1
% predicted group 
had greater COPD-related costs than those in the high FEV
1
% 
predicted group during both the baseline and follow-up 
periods. Within the 12-month postindex period, patients in 
the low FEV
1
% predicted group had greater COPD-related 
utilization, including inpatient hospitalizations, physician 
office visits, other outpatient services, and pharmacy claims 
and associated costs. These findings are consistent with 
previous research, which demonstrated improvements in 
FEV
1
% predicted were significantly related to a decrease in 
COPD symptoms, as well as reduced COPD exacerbations 
and rescue-medication use.7,8,11,13–15 In contrast to findings 
from previous studies using only administrative claims 
data,37–41 our results, which included both a claims-based 
COPD exacerbation indicator and an FEV
1
 status indicator 
from medical records, showed that in analyses that included 
both variables, prior claims-based exacerbations were no 
longer significantly associated with postindex exacerbations 
when FEV
1
 status was included in multivariable analyses.
Multivariable modeling identified LAMAs (single or 
combination therapy) as predictive of fewer COPD exacer-
bations, which is consistent with clinical studies supporting 
the efficacy of LAMAs in reducing COPD exacerbations.42–45 
Conversely, the multivariable analyses identified LABAs 
(single or combination therapy) as predictive of COPD 
exacerbations, a result likely due to indication bias that 
ICS–LABA combinations are likely to be prescribed to 
more severe COPD patients or those with a history of 
exacerbations,43,46 and the vast majority (96.6%) of patients 
on baseline LABA therapies were taking ICS–LABA com-
bination therapies in this study. Additionally, several studies 
identified LAMAs to be the superior therapy over LABAs, 
when compared, in decreasing the risk for moderate-to-severe 
COPD exacerbations.42–45
By using both administrative claims and medical records 
from a large US managed-care population, this study 
describes the impact of lung function on HCRU and costs in a 
real-world population. While it has been well established that 
poor lung function is correlated with increased symptoms and 
exacerbations,7–17 and that exacerbations are associated with 
increased costs,16,17 the study results expand upon previous 
findings of the relationship between clinically determined 
lung function measured by spirometry, HCRU, and costs 
using more recent data compared to previous studies.18–30 
The study results confirm that lung function (FEV
1
) may be 
a useful way for providers to identify and monitor respira-
tory impairment in COPD patients. Payers should recognize 
the importance of lung function as it relates to health care 
utilization and costs. Therefore, health plans may want to 
encourage providers to conduct periodic spirometry testing 
for optimal management of COPD patients.
The study results need to be interpreted in light of several 
study limitations. As with all claims-based analyses, the study 
results may not be generalizable to patients with other types 
of health insurance or those living outside the US, because all 
study participants were members of a large US commercial 
health plan. Data were obtained from administrative claims, 
which are primarily intended for reimbursement rather than 
research purposes. The claims may have contained unde-
tected coding errors, incomplete claims, unreliable clinical 
coding, or other unobservable factors that may have influ-
enced the study outcomes.
There are also limitations associated with the use of medi-
cal record data. A high proportion of patients were excluded 
from the analyses because they had no spirometry results 
documented in their medical records during the observation 
period, despite having a medical claim indicating a spirom-
etry test. Because spirometry is the most objective means of 
measuring COPD severity and is required for confirmation 
of a COPD diagnosis,10 and patients had at least one medical 
claim for a spirometry test during the medical record review 
period, the lack of spirometry results may be a reflection of 
incomplete record-keeping or documentation issues rather 
than an indication that spirometry tests were not performed. 
Also, other issues involving use of medical records include 
missing medical records, the inability to locate needed 
information in the medical record, and vague, incomplete, 
or illegible medical records. In addition, data collected from 
medical record abstractions may contain measurement errors 
due to inconsistent coding of data into categories and mis-
takes in transcription of information from medical records 
to a computer database. Furthermore, facilities that provided 
medical records may be different from those that did not 
respond to requests or refused to participate.
Finally, several limitations were related to the study 
design. Data were collected at one point in time (ie, changes 
in postbronchodilator FEV
1
% predicted over time were not 
captured). In addition, FEV
1
 measurements may not be com-
parable, since they are highly variable and may be influenced 
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by a number of technical and measurement factors and 
seasonal and diurnal variation, which may not be controlled 
for using the observational study design. Lastly, the patient 
cohort was stratified into two groups (high [mild or moder-
ate] vs low [severe or very severe]) instead of four groups 
according to the classification of severity of airflow limitation 
in COPD specified in the 2014 GOLD report.2 However, in 
this study sample, we did not expect significant clinical and 
cost differences between the mild and moderate groups or 
severe and very severe groups based on our exploration of 
the data.
Conclusion
Real-world data demonstrate that patients with COPD who 
have low FEV
1
% predicted levels use more COPD medica-
tions, have more COPD exacerbations, and incur higher 
COPD-related health care costs than patients with COPD 
who have high FEV
1
% predicted levels. Health plans should 
encourage spirometry testing by providers as a means of 
monitoring respiratory impairment of patients with COPD 
to improve the management of their care.
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Supplementary materials
Figure S1 Claim-based sample identification process.
Note: *Index date, date of first medical claim for spirometry during intake period from July 1, 2012 to June 30, 2013.
Abbreviation: eD, emergency department.
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Figure S2 Medical record sample identification process.
Note: *Medical records received after medical record abstraction cutoff date.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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